维普中文期刊产品整合服务
32篇 您的检索式:作者名="Robinson HE"
    题名 作者 年代 出处 被引量
1Diamonds and Other Exotic Minerals Recovered from Peridotites of the Dangqiong Ophiolite, Western Yarlung-Zangbo Suture Zone, Tibet显示文摘Various combinations of diamond, moissanite, zircon, quartz, corundum, rutile, titanite, almandine garnet, kyanite, and andalusite have been recovered from the Dangqiong peridotites. More than 80 grains of diamond have been recovered, most of which are pale yellow to reddish-orange to colorless. The grains are all 100-200 μm in size and mostly anhedral, but with a range of morphologies including elongated, octahedral and subhedral varieties. Their identification was confirmed by a characteristic shift in the Raman spectra between 1325 cm^(-1) and 1333 cm^(-1), mostly at 1331.51 cm^(-1) or 1326.96 cm^(-1). Integration of the mineralogical, petrological and geochemical data for the Dongqiong peridotites suggests a multi-stage formation for this body and similar ophiolites in the Yarlung-Zangbo suture zone. Chromian spinel grains and perhaps small bodies of chromitite crystallized at various depths in the upper mantle, and encapsulated the UHP, highly reduced and crustal minerals. Some oceanic crustal slabs containing the chromian spinel and their inclusion were later trapped in suprasubduction zones(SSZ), where they were modified by island arc tholeiitic and boninitic magmas, thus changing the chromian spinel compositions and depositing chromitite ores in melt channels.XIONG Fahui YANG Jingsui ROBINSON Paul T. XU Xiangzhen BA Dengzhu LI Yuan ZHANG Zhongming RONG He 2016Acta Geologica Sinica(English Edition)2016,90,2:20
2Diamonds Discovered from High–Cr Podiform Chromitites of Bulqiza,Eastern Mirdita Ophiolite,Albania显示文摘Various combinations of diamond, moissanite, zircon, corundum, rutile and titanitehave been recovered from the Bulqiza chromitites. More than 10 grains of diamond have been recovered, most of which are pale yellow to reddish–orange to colorless. The grains are all 100–300 μm in size and mostly anhedral, but with a range of morphologies including elongated, octahedral and subhedral varieties. Their identification was confirmed by a characteristic shift in the Raman spectra between 1325 cm^(-1) and 1333 cm^(-1), mostly at 1331.51 cm^(-1) or 1326.96 cm^(-1). This investigation extends the occurrence of diamond and moissanite to the Bulqiza chromitites in the Eastern Mirdita Ophiolite. Integration of the mineralogical, petrological and geochemical data of the Bulqiza chromitites suggests their multi–stage formation. Magnesiochromite grains and perhaps small bodies of chromitite formed at various depths in the upper mantle, and encapsulated the ultra–high pressure, highly reduced and crustal minerals. Some oceanic crustal slabs containing the magnesiochromite and their inclusion were later trapped in suprasubduction zones, where they were modified by tholeiitic and boninitic arc magmas, thus changing the magnesiochromite compositions and depositing chromitite ores in melt channels.XIONG Fahui YANG Jingsui ROBINSON Paul T. DILEK Yildirim MILUSHI Ibrahim XU Xiangzhen ZHOU Wenda ZHANG Zhongming RONG He 2017Acta Geologica Sinica(English Edition)2017,91,2:9
3Components of complex interventions for healthcare: A narrative synthesis of qualitative studies显示文摘Objective:Qualitative research on therapeutic components is necessary to evaluate the efficacy of complex interventions in healthcare.As few qualitative syntheses have been conducted,this study aimed to derive a new conceptual framework for understanding the components of complex interventions and provide evidence for the implementation and evaluation of complex healthcare interventions.Methods:A systematic search of seven databases was conducted to identify qualitative studies that explored components of complex healthcare interventions.Meta-ethnography was used to analyze the data and thematic analysis was used to build the conceptual framework.Results:Of the 35 included studies,most complex interventions were non-pharmacological,with cancer accounting for 22%,mental health for 14%,and stroke for 8%.Half of the studies were conducted in the United Kingdom.Three main categories emerged:what should healthcare workers do?what qualifications should they have?and what should patients do?Five main themes were identified:psychological,biological,cognitive and behavioral,environmental,and social support.Conclusion:This analysis provides a reference for designing components of complex interventions in further studies.Sisi Ma He Yu Ning Liang Sijia Zhu Xun Li Nicola Robinson Jianping Liu 2020Journal of Traditional Chinese Medical Sciences2020,7,2:2
4Maternal outcomes in pregnancies complicated by obesity 显示文摘Robinson HE O'Connellcm Joseph KS 2005Obstet Gynecol2005,106,6:1
5Peripheral neural correlates of magnitude of cutaneous pain and byperalgesia: simultaneous recordings in humans of sensory judgments of pain and evoked responses in nociceptors with C-fibers 显示文摘Torebjork HE LaMotte RH Robinson CJ 1984J Neuropbysiol1984,51,2:1
6Efficacy and safety of alirocumab as add- on therapy in high-cardiovascular- risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 rag): design and rationale of the ODYSSEY OPTIONS Studies显示文摘ROBINSON JG COLHOUN HM BAYS HE 2014Clin Cardiol2014,37,10:1
7Maternal oul- comes in pregnancies complicated by obesity 显示文摘Robinson HE O'Connell CM Joseph KS 2005Obstet Gynecol2005,106,6:1
8CWR22: androgen--dependent xenograft model derived from a primary human prostatic carcinoma显示文摘Wainstein MA He F Robinson D 1994Cancer Res1994,54,23:1
9A tyrosine kinase profile of prostate carcinoma显示文摘Robinson D He F Pretlow T 1996Proc Natl Acad Sci USA1996,93,12:1
10Maternal outcomes in pregnancies complicated by obesity显示文摘Robinson HE O'Connell CM Joseph KS 0,,06:1
11Efficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvas- tatin (20 or 40 nag) or rosuvastatin (10 or 20 mg): design and ratio- nale of the ODYSSEY OPTIONS Studies 显示文摘Robinson JG Colhoun HM Bays HE 2014Clin Cardiol2014,37,10:1
12IL12B expression is sustained by a heterogenous population of myeloid lineages during tuberculosis 显示文摘Reeme AE Miller HE Robinson RT 2013Tuberculosis (Edinb)2013,93,3:1
13Randomised controlled trial of faecal-occult-blood screening for colorectal cancer显示文摘Jack D Hardcastle Jocelyn O Chamberlain Michael HE Robinson Susan M Moss Satya S Amar Tom W Balfour Peter D James Christine M Mangham 1996The Lancet1996,,9040:1
14Efficacy ami safety of a1irocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin(20 or 40 mg) or rosuvastatin( 10 or 20 mg) : design and rationale of the ODYSSEY OPtionS studies显示文摘Robinson JG Colhoun HM Bays HE et a1 2014Clin Cardiol2014,37,10:1
15A tyrosine kinase profile of prostate carcinoma 显示文摘Robinson D He F Pretlow T 1996Proc Natl Aead Sei U S A1996,93,12:1
16Intensive versus conventional glucose control in critically ill patients显示文摘NICE-SUGAR Study Investigators Finfer S Chittock DR Su SY Blair D Foster D Dhingra V Bellomo R Cook D Dodek P Henderson WR He bert PC Heritier S Heyland DK MeArthur C McDonald E Mitchell I Myburgh JA Norton R Potter J Robinson BG Roneo JJ 2009N Engl J Med2009,360,13:1
17Efficacy and safety of alirocumab as add-on therapy in high-cardiovascu- lar-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin ( 10 or 20 mg) : design and rationale of the ODYSSEY OP- TIONS Studies 显示文摘Robinson JG Colhoun HM Bays HE 2014Clinical cardiology2014,37,10:1
18Cefotetan induced life-threatening haemolysis显示文摘Robinson HE Maxwell EL Prince HM 2006Med J Aust2006,184,5:1
19Maternal outcomesin pregnancies complicated by obesity 显示文摘Robinson HE O Connell CM Joseph KS 2005Obstet Gynecol2005,106,6:1
20Maternal outcomes in preg- nancies complicated by obesity 显示文摘Robinson HE O' Connell CM Joseph KS 2005Obstet Gynecol2005,106,6:1
返回顶部 每页显示:
共2页 首页 上一页 第1页 下一页 末页 /2 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费